Faes Farma in figures

We are a national pharmaceutical company founded in 1933 with a strong presence in Spain and Portugal, and we maintain extensive and growing international development, with a presence in numerous countries and exports of raw materials and finished pharmaceutical products to an increasing number of nations.

To develop our overall research, production, and commercialization of pharmaceutical products, including our animal nutrition business, we have a workforce of over 1,766 people (as of the end of 2022) in our various offices and subsidiaries.

Our headquarters, production facilities, offices, and R&D are in Leioa (Vizcaya), and we have offices in Madrid and Barcelona. Our subsidiaries in Europe are in Portugal and Italy (with a 51% stake). We have a strong presence in LATAM with subsidiaries in Colombia, Mexico, Chile, Ecuador, Peru, and Guatemala (covering Central America and the Dominican Republic: CAD). Faes Farma also has a presence in Africa through our subsidiary in Nigeria.

In addition, at Faes Farma, we work in the animal nutrition and health sector (Farm Faes) with our companies Ingaso Farm, Tecnovit AND Capselos.

Faes Farma’s three main commercialized molecules are bilastine, calcifediol, and mesalazine. We highlight bilastine, an antihistamine molecule resulting from our commitment to pharmaceutical research, which has been licensed in over 100 countries worldwide. Including all the business areas in which they are present, these three molecules represent 36.8% of the Group’s revenues (35.3% in 2021), and the increase in their sales in 2022 accounts for 56% of the total revenue growth of the Group.

The Group’s gross investments during the past year reached €92 million, the highest figure in the Group’s history, following a 10.4% increase. These investments were mainly aimed at the construction of the new pharmaceutical production factory, which will increase production capacity and consolidate our position as an integrated pharmaceutical group.

The Faes Farma Group ended 2022 with revenues of €461.7 million, representing a 7.7% growth compared to the previous year. This positive trend reinforces the Group’s solid financial position.

Consolidated Net Profit in 2022 reached €89.5 million, an 8.6% increase compared to 2021, achieving for the seventh consecutive year the highest profit in our history, and with an EBITDA of €120.7 million, a +6% increase over 2021.